IE51175B1 - Allergens modified with polysarcosines - Google Patents
Allergens modified with polysarcosinesInfo
- Publication number
- IE51175B1 IE51175B1 IE844/81A IE84481A IE51175B1 IE 51175 B1 IE51175 B1 IE 51175B1 IE 844/81 A IE844/81 A IE 844/81A IE 84481 A IE84481 A IE 84481A IE 51175 B1 IE51175 B1 IE 51175B1
- Authority
- IE
- Ireland
- Prior art keywords
- allergen
- polysarcosine
- conjugate according
- bound
- rye
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 70
- 108010082974 polysarcosine Proteins 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 4
- 230000007815 allergy Effects 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 12
- 238000009739 binding Methods 0.000 claims description 10
- 244000036975 Ambrosia artemisiifolia Species 0.000 claims description 6
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 claims description 6
- 235000003484 annual ragweed Nutrition 0.000 claims description 6
- 235000006263 bur ragweed Nutrition 0.000 claims description 6
- 235000003488 common ragweed Nutrition 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 235000009736 ragweed Nutrition 0.000 claims description 6
- 241000209504 Poaceae Species 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- 239000000872 buffer Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229960004784 allergens Drugs 0.000 description 8
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940043230 sarcosine Drugs 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 241000209082 Lolium Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940046528 grass pollen Drugs 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JKAPWXKZLYJQJJ-UHFFFAOYSA-N 2,4-dichloro-6-methoxy-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(Cl)=N1 JKAPWXKZLYJQJJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- CBWFTZNMONHKNZ-UHFFFAOYSA-N 2-[methyl(phenylmethoxycarbonyl)amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OCC1=CC=CC=C1 CBWFTZNMONHKNZ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UATJOMSPNYCXIX-UHFFFAOYSA-N Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- -1 cyclic anhydrides Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8012294 | 1980-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE810844L IE810844L (en) | 1981-10-15 |
| IE51175B1 true IE51175B1 (en) | 1986-10-29 |
Family
ID=10512782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE844/81A IE51175B1 (en) | 1980-04-15 | 1981-04-14 | Allergens modified with polysarcosines |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4609547A (enExample) |
| EP (1) | EP0038154B1 (enExample) |
| JP (1) | JPS56161332A (enExample) |
| AU (1) | AU535109B2 (enExample) |
| CA (1) | CA1171356A (enExample) |
| DE (1) | DE3160926D1 (enExample) |
| ES (1) | ES501376A0 (enExample) |
| GR (1) | GR75221B (enExample) |
| IE (1) | IE51175B1 (enExample) |
| NZ (1) | NZ196775A (enExample) |
| PT (1) | PT72847B (enExample) |
| ZA (1) | ZA812340B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077158A1 (en) * | 1981-10-09 | 1983-04-20 | Beecham Group Plc | Modified allergens |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US5116612A (en) * | 1987-06-23 | 1992-05-26 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
| US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
| US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
| US6075121A (en) * | 1990-05-15 | 2000-06-13 | Chiron Corporation | Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such |
| DE69739174D1 (de) | 1997-10-30 | 2009-01-29 | Leti Sl Lab | Tolerogenefragmente aus natürlichen allergenen |
| NZ512456A (en) * | 1998-11-30 | 2003-10-31 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens |
| US6869519B2 (en) * | 2001-09-27 | 2005-03-22 | National Institute Of Advanced Industrial Science And Technology | Electrolytic process for the production of metallic copper and apparatus therefor |
| SI1524994T1 (sl) | 2002-07-19 | 2011-08-31 | Cytos Biotechnology Ag | Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe |
| US7037535B2 (en) * | 2002-11-19 | 2006-05-02 | Kimberly-Clark Worldwide, Inc. | Method and composition for neutralizing house dust mite feces |
| US7585518B2 (en) * | 2002-11-19 | 2009-09-08 | Kimberly-Clark Worldwide, Inc. | Products and methods for maintaining or increasing ceramide levels in skin |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| ZA200507562B (en) | 2003-03-26 | 2006-11-29 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| US20050019379A1 (en) * | 2003-07-22 | 2005-01-27 | Kimberly-Clark Worldwide, Inc. | Wipe and methods for improving skin health |
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3619371A (en) * | 1967-07-03 | 1971-11-09 | Nat Res Dev | Production of a polymeric matrix having a biologically active substance bound thereto |
| US4180562A (en) * | 1973-05-08 | 1979-12-25 | Northwestern University | Glutaraldehyde polymerized ragweed antigen E preparation for treatment of allergic patients sensitive to ragweed pollen |
| GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
| US4152411A (en) * | 1977-07-27 | 1979-05-01 | Akzona Incorporated | High specific activity labeled substances |
| US4215036A (en) * | 1978-08-15 | 1980-07-29 | Research Corporation | Modified grass pollen antigens |
-
1981
- 1981-04-06 EP EP81301476A patent/EP0038154B1/en not_active Expired
- 1981-04-06 DE DE8181301476T patent/DE3160926D1/de not_active Expired
- 1981-04-08 ZA ZA00812340A patent/ZA812340B/xx unknown
- 1981-04-09 NZ NZ196775A patent/NZ196775A/xx unknown
- 1981-04-13 PT PT72847A patent/PT72847B/pt unknown
- 1981-04-13 GR GR64674A patent/GR75221B/el unknown
- 1981-04-14 IE IE844/81A patent/IE51175B1/en unknown
- 1981-04-14 ES ES501376A patent/ES501376A0/es active Granted
- 1981-04-14 CA CA000375432A patent/CA1171356A/en not_active Expired
- 1981-04-14 AU AU69523/81A patent/AU535109B2/en not_active Ceased
- 1981-04-15 JP JP5685081A patent/JPS56161332A/ja active Pending
-
1984
- 1984-04-26 US US06/603,666 patent/US4609547A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0038154B1 (en) | 1983-09-21 |
| AU535109B2 (en) | 1984-03-01 |
| IE810844L (en) | 1981-10-15 |
| NZ196775A (en) | 1983-12-16 |
| ES8300474A1 (es) | 1982-11-01 |
| PT72847B (en) | 1982-03-30 |
| US4609547A (en) | 1986-09-02 |
| DE3160926D1 (en) | 1983-10-27 |
| ZA812340B (en) | 1982-04-28 |
| PT72847A (en) | 1981-05-01 |
| GR75221B (enExample) | 1984-07-13 |
| CA1171356A (en) | 1984-07-24 |
| AU6952381A (en) | 1981-10-22 |
| JPS56161332A (en) | 1981-12-11 |
| EP0038154A1 (en) | 1981-10-21 |
| ES501376A0 (es) | 1982-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE51175B1 (en) | Allergens modified with polysarcosines | |
| US4158705A (en) | Antigen-protein complex for blocking allergic reactions | |
| DE69934228T2 (de) | Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen | |
| Van Eerd et al. | Determination of the complete amino acid sequence of bovine cardiac troponin C | |
| EP0213391A2 (en) | Antigenic modification of polypeptides | |
| DE2717741C2 (enExample) | ||
| DE3211263A1 (de) | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung | |
| IE42395B1 (en) | Production of long acting insulin preparations | |
| AU2018383708A1 (en) | Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis | |
| JP2791957B2 (ja) | ホロレナ・クルタくも毒液から単離されたポリペプチド類 | |
| JPH08502498A (ja) | 低アレルゲン性タンパク質 | |
| EP2149051B1 (de) | Verfahren und immunabsorbentien zur spezifischen detektion und absorption zöliakie- und dermatitis herpetiformis assoziierter antikörper | |
| Ventas et al. | Purification and characterization of Lep d I, a major allergen from the mite Lepidoglyphus destructor | |
| DE60226324T2 (de) | Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose | |
| KR20230133294A (ko) | 화합물 또는 그 염, 및 그것들에 의해 얻어지는 항체 | |
| DE3014582C2 (enExample) | ||
| EP1108738A2 (en) | Immunostimulating carrier for vaccines | |
| Ehrlich et al. | Isolation of an active heavy-chain variable domain from a homogeneous rabbit antibody by cathepsin B digestion of the aminoethylated heavy chain | |
| CA1175743A (en) | Modified allergens | |
| JP3334143B2 (ja) | 生理活性ペプチド | |
| US5945104A (en) | Peptides for anti-allergy treatment | |
| DE2646223C2 (enExample) | ||
| EP0077158A1 (en) | Modified allergens | |
| Williams et al. | Rheumatoid factors from patients with rheumatoid arthritis react with Des‐Lys58‐β2m, modified β2‐microglobulin | |
| CA1264000A (en) | Antigenic modification of polypeptides |